This site is intended only for all Healthcare Professionals residing in South Africa




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



About ZAVICEFTAClinical EfficacySafety and tolerabilityThe ZAVICEFTA patientFull prescribing informationVideo Resources
Prescribing information available at the bottom of the page

Broad-spectrum coverage

Mechanism of action

Tab Number 3

ZAVICEFTA® is a broad spectrum cephalosporin active against many Gram-negative and Gram-positive bacterial pathogens in vitro. ZAVICEFTA® inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including ESBLs, KPC and OXA-48 carbapenemases, and AmpC enzymes. 2
FootnoteAvibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many class D enzymes.

Watch the video below to learn how the combination of ceftazidime and avibactam inhibits a broad range of Gram-negative resistance mechanisms.


AbbreviationsBL - β-lacatamase; BLI - β-lactamase inhibitor; cIAI - complicated intra-abdominal infection; CRE - carbapenem-resistant Enterobacteriaceae; cUTI - complicated urinary tract infection; ESBL - extended-spectrum β-lacatamase; HABP - hospital-acquired bacterial pneumonia; KPC - Klebsiella pneumoniae carbapenemase; MDR - multidrug-resistant; OXA - oxacillinase; VABP - ventilator-associated bacterial pneumonia.
ReferencesLiscio JLet al. Int J Antimicrob Agents 2015;46:266-71; ZAVICEFTA®South African Approved Professional Information, date of publication: 21 September 2021; Nicolau DPet al. J Antimicrob Chemother 2015;70:2862-9; Stone GG, et al. Antimicrob Agent Chemother 64:e02356-19; Mazuski JEet al. Surg Infect (Marchmnt) 2017;18:1-76; Pogue JMet al. Clin Infect Dis 2019;68:519-24; Zhanel GGet al. Drugs 2013:73:159-77; Lagacé-Wiens P, et al. Core Evid 2014;9:13-25. Bush K,  Int J Antimicrob Agents 2015;46:483-93; Wright Het al. Clin Microbiol Infect 2017;23:704-12; Sader H, et al. Diagn Microbiol Infect Dis 2015;83:389-94; Walkty A,et al. Antimicrob Agents Chemother 2011;55:2992-4; Carmeli Y, et al. Lancet Infect Dis 2016;16:661-73; Torres A,et al. Lancet Infect Dis 2018;18:285-295; Wagenlehner FM,  et al. Clin Infect Dis 2016;63:754-62; Mazuski JE,  et al. Clin Infect Dis 2016;62:1380-9
View ZAVICEFTA® Prescribing information Loading
*ZAVICEFTA ® South African Approved Professional Information date of publication (21 September 2021). PP-ZVA-ZAF-0029
Clinical Information  Support & Services See safety outcomes Loading See efficacy results Loading

Copyright ©2023 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).


Copyright © 2023. Pfizer Laboratories (Pty) Ltd. All rights reserved

For South Africa Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable